

FLORIDA | Board of Osteopathic Medicine

April 10, 2018 Conference Call Meeting



DRAFT MEETING MINUTES
Board of Osteopathic Medicine
General Business Conference Call Meeting
April 10, 2018
12:30 p.m.

1 (888) 670-3525
6607485549

The meeting was called to order by Dr. Sandra Schwemmer, Chair, at approximately 4:32 p.m.

Those present for all or part of the meeting included the following:

MEMBERS PRESENT:

Sandra Schwemmer, DO, Chair
Joel B. Rose, DO, Vice Chair
Anna Hayden, DO
Bridget Bellingar, DO
Valerie Jackson, Consumer Member
Alicja Janson, Consumer Member
Michelle R. Mendez, DO

MEMBERS ABSENT

None

COURT REPORTER:

Audio Recorded

OTHERS PRESENT:

Chris Nuland, FAFP (Florida Academy of Family Physicians)
Ryan Kimmey, FOMA (Florida Osteopathic Medicine Association)
Mary Thomas, FMA (Florida Medical Association)
Beth Brunner, FCEP/FEMF (Florida College of Emergency Physicians/Florida Emergency Medicine Foundation)

BOARD STAFF PRESENT:

Kama Monroe, Executive Director
Carol Taylor, Program Administrator
Christa Peace, Regulatory Specialist III

BOARD COUNSEL

Donna McNulty, Board Counsel
Nancy Murphy, O&M Consultant I

Please note that the meeting minutes reflect the actual order that agenda items were discussed during the meeting and may differ from the agenda outline.

REVIEW AND APPROVAL OF MINUTES

Tab 1 – February 22, 2018 Meeting Minutes

Motion: by Dr. Schwemmer, seconded by Dr. Rose, to accept the minutes. Motion carried.

INTRODUCTORY REMARKS:

Board Counsel, Donna McNulty identified the purpose of the meeting. Board Counsel gave an overview of HB21 which was recently passed by the governor. The proposed draft rule language requires all CME prescribers to complete a two hour controlled substances course by January 2019. This bill requires the board members to participate in rulemaking for controlled substances.

Board Counsel informed the board that the Board of Medicine plans to send a letter to the Board of Osteopathic Medicine and the other prescribing boards to request they form a rulemaking committee. Ms. McNulty encouraged the Board of Osteopathic Medicine to vote on representatives from their board to participate.

Dr. Rose indicated a desire to work with the Board of Medicine and other prescribing boards with at least three members on rule-making for all controlled substances, in addition to acute pain for HB21.

Discussion ensued which included the number of representatives desired on the committee and who would participate. It was a consensus that three participants is the ideal number, but that the Board of Osteopathic Medicine should have at least the same representation on the committee as the Board of Medicine. Doctors Mendez, Rose, and Schwemmer all indicated a desire to participate on the committee. After discussion:

Motion: by Dr. Hayden, seconded by Dr. Mendez, to have the same amount of representation on the committee as the Board of Medicine. Motion carried.

Following the vote Dr. Hayden asked for clarity regarding the names of the participants. Dr. Schwemmer clarified the Board of Osteopathic Medicine will align participants with the Board of Medicine and the other boards, once the letter is received from the Board of Medicine.

RULE DISCUSSION

HB 21 – Controlled Substances

Tab 2. HB 21 Enrolled Version

Tab 3. Final Bill Analysis for HB 21

Tab 4. 64B15-13.0025 - Draft Rule Language for Initial CME course

Tab 5. Course Requests

- a. Email from Mary Thomas
BOOM Letter Opioid Course Approval
FMA Accreditation Documentation
FMA Safe Prescribing of Controlled Substances curriculum
- b. Email from Chris Nuland
FAFP Safe Opiate Prescribing: A Review of the CDC Guidelines
Accreditation Letter 2016
- c. Email from Beth Brunner
FCEP_FEMF Opioid CE Outline 032618
- d. Email From FOMA

MATERIALS RECEIVED AFTER AGENDA PUBLISHED

Beth Brunner withdrawal of request for ce course approval [goes with Tab 5 (c)]
E-mail from Mary Thomas regarding FMA and FOMA CE course [goes with Tab 5 (a)]
Opioids and controlled substances
FOMA letter and accreditation [goes with Tab 5 (d)]

MATERIALS RECEIVED 4.9.18

E-mail from Chris Nuland dated 4.9.18 [goes with Tab 5 (b)]
Opioid FAFP HB 21

Beth Brunner from the FCEP requested the continuing education course previously submitted and withdrawn from the instant agenda be placed back on the agenda and reviewed.

After discussion:

Motion: by Dr. Hayden, seconded by Dr. Rose, to include the continuing education course from FCEP for review on the instant agenda. Good cause shown was identified as being in the interest of expediency of getting courses out there, due to the fact the deadline to complete the 2-hour course is January 31, 2019. Motion carried

Discussion of tabs 4 & 5, the draft rule language for Rule 64B15-13.0025 and the continuing education courses submitted for review and approval, ensued.

Motion: by Dr. Hayden, seconded by Dr. Mendez, to approve the continuing education courses offered by FMA, FOMA, FCEP, and FAFP and the proposed draft rule language for Rule 64B15-13.0025 as presented. Motion carried.

Motion: by Dr. Mendez, seconded by Dr. Rose, that the proposed changes will not make an adverse impact on small business and proposed changes would not directly or indirectly increase regulatory costs to any entity including government in excess of \$200,000.00 in aggregate in Florida within one year after the implementation of the rule. No SERC is needed and no legislative ratification is needed. Motion carried.

Motion: by Rose, seconded by Ms. Jackson, to find that a violation of this rule or any part of this rule would not be considered a minor violation. Motion carried.

Ms McNulty clarified that the courses approved by the Board during this meeting can be offered immediately.

Adjourn: 1:08 p.m.

Next Meeting: May 18, 2018
Location: Tallahassee
9:00 a.m.